This study is about understanding the safety and effectiveness of a new medicine, RO7790121, for people with advanced MASH liver fibrosis. MASH stands for Metabolic Dysfunction-Associated Steatohepatitis, which is a liver disease linked to fat build-up and inflammation. Pharmacokinetics (PK) studies how the medicine moves through your body, while pharmacodynamics (PD) looks at the effects it has. Immunogenicity checks if the body reacts to the medicine.
- Participants need to be ready for contraception and have a body mass index (BMI) between 25 and 45.
- They should have a fibrosis score of F3 or F4, indicating severe liver scarring.
- The study excludes people with recent major weight changes, certain surgeries, or other serious health problems.
It's important to know that people with uncontrolled blood pressure or diabetes, recent or past liver problems, or significant alcohol use cannot be part of this study. The study will help determine if RO7790121 is safe and effective for treating advanced liver fibrosis in MASH patients.
How understandable was the trial content above?
Hard to understand
Easy to understand